HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.108.060756v1 50/5/818    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koole, M. Articles by Van Laere, K. Search for Related Content PubMed PubMed Citation Articles by Koole, M. Articles by Van Laere, K.

Whole-Body Biodistribution and Radiation Dosimetry of ¹⁸F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging

¹ Nuclear Medicine, University Hospital and K.U. Leuven, Leuven, Belgium; ² GE Healthcare Medical Diagnostics Research and Development, Amersham, United Kingdom; ³ Laboratory for Cognitive Neurology, K.U. Leuven, Leuven, Belgium; ⁴ Psychiatry Department, UZ Leuven, Leuven, Belgium; ⁵ Division of Neuroscience, Faculty of Medicine, Imperial College London, London, United Kingdom; and ⁶ Neurology Department, UZ Leuven, Leuven, Belgium

Correspondence: For correspondence or reprints contact: Koen Van Laere, Division of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. E-mail: koen.vanlaere{at}uzleuven.be

We have characterized the biodistribution and dosimetry of ¹⁸F-3'-F-6-OH-BTA1 (¹⁸F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51–74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of ¹⁸F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. ¹⁸F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 µGy/MBq, respectively). The mean effective dose was 33.8 ± 3.4 µSv/MBq, a dose comparable to that of many other ¹⁸F-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of ¹⁸F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.

Key Words: amyloid imaging • ¹⁸F-GE067 • PET • dosimetry • biodistribution • healthy subjects

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  

This article has been cited by other articles:

				N. Nelissen, K. Van Laere, L. Thurfjell, R. Owenius, M. Vandenbulcke, M. Koole, G. Bormans, D. J. Brooks, and R. Vandenberghe Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease J. Nucl. Med., August 1, 2009; 50(8): 1251 - 1259. [Abstract] [Full Text] [PDF]